GSK中国总经理余慧明：创新合作，共拓中国健康未来

Core Insights - The China International Import Expo (CIIE) serves as a vital bridge for global trade resources and promotes the integration of domestic and international industries, showcasing China's market vitality and providing a stable development platform for global trade [1][3] Group 1: CIIE's Role and Impact - Since its inception in 2018, CIIE has transformed exhibits into commodities and exhibitors into investors, highlighting its role in international procurement, investment promotion, cultural exchange, and open cooperation [3] - GSK has participated in CIIE for eight consecutive years, evolving from a witness to a participant and promoter of China's economic development [3][5] - CIIE is recognized as a high-quality platform that reflects China's reform and opening-up achievements, enhancing the business environment for foreign enterprises like GSK [3][5] Group 2: GSK's Commitment to China - GSK views China as a core growth engine and a significant source of global innovation, particularly in biopharmaceuticals and artificial intelligence [5][10] - GSK's commitment to China includes establishing a global innovation center and aligning its product pipeline with China's health strategies [10][12] Group 3: Innovation and Collaboration - The Chinese innovative pharmaceutical sector has seen explosive growth, with domestic companies emerging as key players in global pharmaceutical innovation [6][11] - CIIE facilitates the rapid introduction of innovative drugs and medical solutions to Chinese patients, enhancing collaboration between international and domestic pharmaceutical resources [6][11] - GSK plans to showcase approximately 20 innovative products at this year's CIIE, focusing on respiratory, immunology, and oncology areas [8][10] Group 4: Strategic Partnerships - GSK collaborates with local partners to enhance the accessibility of its products and supports various health initiatives in China [11][12] - The company is actively exploring diverse collaboration models with local biopharmaceutical firms, including a recent agreement with Hengrui Medicine to co-develop up to 12 innovative drugs [12][13] Group 5: Future Outlook - CIIE exemplifies the deep integration of China with the global economy and serves as a platform for multinational companies to connect with Chinese market demands [13] - GSK is committed to increasing its investment in China, focusing on local innovation capabilities and creating a win-win industrial ecosystem [13]